[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group]

Pneumonol Alergol Pol. 2007;75(1):88-94.
[Article in Polish]

Abstract

Small-cell lung cancer is characterized by an aggressive clinical course with high tendency for early dissemination. At presentation, patients are usually symptomatic and with hilar or mediastinal mass at radiography. Staging should be focused on identifying any evidence of distant spread. Chemotherapy including cisplatin and etoposide is a cornerstone of treatment for all patients. Limited-stage disease should be managed by chemotherapy combined with concurrent chest irradiation. All patients who achieve complete response should be considered for elective cranial irradiation. Surgical treatment may be used in highly selected patients with TNM stage I disease, and surgery should always be combined with chemotherapy. Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivors should undergo careful monitoring for development of a second primary tumour.

Publication types

  • English Abstract
  • Practice Guideline

MeSH terms

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary
  • Carcinoma, Small Cell / diagnosis*
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Small Cell / secondary
  • Carcinoma, Small Cell / therapy*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy / standards
  • Etoposide / administration & dosage
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Neoplasm Recurrence, Local / prevention & control
  • Neoplasm Staging
  • Neoplasms, Multiple Primary / prevention & control
  • Pneumonectomy
  • Prognosis
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Etoposide
  • Cisplatin